Equities research analysts expect that Centogene N.V. (NASDAQ:CNTG) will announce earnings per share of ($0.16) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Centogene’s earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.18). The firm is expected to report its next earnings report on Thursday, March 5th.
On average, analysts expect that Centogene will report full year earnings of ($4.03) per share for the current fiscal year, with EPS estimates ranging from ($4.14) to ($3.92). For the next financial year, analysts forecast that the firm will post earnings of ($1.15) per share, with EPS estimates ranging from ($1.20) to ($1.09). Zacks’ EPS averages are an average based on a survey of analysts that cover Centogene.
Centogene (NASDAQ:CNTG) last issued its quarterly earnings results on Thursday, December 5th. The company reported ($14.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($19.13) by $4.68. The firm had revenue of $12.94 million for the quarter, compared to the consensus estimate of $12.25 million.
Several research firms have recently weighed in on CNTG. BTIG Research initiated coverage on Centogene in a research note on Monday, December 2nd. They set a “buy” rating and a $18.00 price objective for the company. Robert W. Baird began coverage on Centogene in a report on Tuesday, December 3rd. They set an “outperform” rating and a $15.00 price objective for the company. Evercore ISI began coverage on Centogene in a report on Monday, December 2nd. They set an “outperform” rating and a $17.00 price objective for the company. Finally, Svb Leerink reiterated an “outperform” rating on shares of Centogene in a report on Monday, December 2nd.
Shares of NASDAQ CNTG opened at $13.66 on Friday. The firm’s fifty day moving average price is $11.27. The company has a debt-to-equity ratio of 1.44, a current ratio of 0.82 and a quick ratio of 0.77. Centogene has a 1 year low of $7.80 and a 1 year high of $15.59.
Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.
Recommended Story: Economic Reports
Get a free copy of the Zacks research report on Centogene (CNTG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.